

Supplementary table: Hepatitis B virus (HBV) infection seroprevalence estimates by country for hepatitis B mathematical model

Country	Hepatitis B virus serological markers included in Goldstein model (%) ^a			
	HBsAg among WCBA	HBeAg among WCBA	Anti-HBc at 5 years old	Anti-HBc at ≥ 30 years old
Bangladesh	7.50 ^b	16.70 ^b	0.76 ^b	52.50 ^b
Bhutan	3.59 [1]	20.00 [1]	10.00 [1]	45.00 [1]
DPR Korea	11.83 [1]	30.00 [1]	25.00 [1]	77.50 [1]
India	3.59 [1]	20.00 [1]	10.00 [1]	45.00 [1]
Indonesia	2.20 [2, 3, 4]	23.55 [2, 3]	25.00 [1]	77.50 [1]
Maldives	3.59 [1]	20.00 [1]	10.00 [1]	45.00 [1]
Myanmar	5.50 ^b	32.70 [5]	25.00 [1]	77.50 [1]
Nepal	1.00 [6]	20.00 [1]	10.00 [1]	45.00 [1]
Sri Lanka	1.75 ^b [7]	20.00 [1]	25.00 [1]	77.50 [1]
Thailand	4.50 [8]	10.70 [9]	1.40 [8]	37.10 [8]
Timor-Leste	2.80 [10]	20.00 [1]	25.00 [1]	77.50 [1]

HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e antigen; anti-HBc: anti hepatitis B core antibody; WCBA: women of child bearing age

^a When more than one study was available, median seroprevalence was calculated unless country had a nationally representative serosurvey in which case the most recent national serosurvey was used

^b Unpublished report

References used for the supplementary table

- [1] Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. *Int J Epidemiol* 2005; 34(6):1329-39.
- [2] Fujiko M, Chalid MT, Turyadi, Ie SI, Maghfira, Syafri, et al. Chronic hepatitis B in pregnant women: is hepatitis B surface antigen quantification useful for viral load prediction? *Int J Infect Dis* 2015;41:83-9.
- [3] Surya IG, Kornia K, Suwardewa TG, Mulyanto, Tsuda F, Mishiro S. Serological markers of hepatitis B, C, and E viruses and human immunodeficiency virus type-1 infections in pregnant women in Bali, Indonesia. *J Med Virol* 2005;75(4):499-503.

- [4] Gunardi H, Zaimi LF, Soedjatmiko, Turyadi, Harahap AR, Muljono DH. Current prevalence of hepatitis B infection among parturient women in Jakarta, Indonesia. *Acta Med Indones* 2014;46(1):3-9.
- [5] Banks T, Kang J, Watts I, Tyrosvoutis ME, Min AM, Tun NW, et al. High hepatitis B seroprevalence and risk factors for infection in pregnant women on the Thailand-Myanmar Border. *J Infect Dev Ctries* 2016;10(4):384-8.
- [6] Shrestha SM, Shrestha S. Chronic hepatitis B in Nepal: an Asian country with low prevalence of HBV infection. *Trop Gastroenterol* 2012;33(2):95-101.
- [7] Padmasiri E, Rajapaksa L, Jayakuru WS, Withana N. The prevalence of hepatitis B surface antigen in the Gampaha district. *Ceylon Med J* 1995;40(1):10-3.
- [8] Posuwan N, Wanlapakorn N, Sa-Nguanmoo P, Wasitthankasem R, Vichaiwattana P, Klinfueng S et al. The Success of a Universal Hepatitis B Immunization Program as Part of Thailand's EPI after 22 Years' Implementation. *PLoS One* 2016; <https://doi.org/10.1371/journal.pone.0150499>.
- [9] Yimnoi P, Posuwan N, Wanlapakorn N, Tangkijvanich P, Theamboonlers A, Vongpunsawad S, Poorvorawan Y. A molecular epidemiology study of the hepatitis B virus in Thailand after 22 years of universal immunization. *J Med Virol* 2016. 88(4):664-673.
- [10] Hall C, Gibbons M, Murphy D, Nourse C. Prevalence of hepatitis B infection in women delivering at a community health centre in Dili, Timor-Leste and discussion of programmatic challenges. *Trans R Soc Trop Med Hyg* 2015;109(4):280-2.